CN1778902A - Non-serum culture medium for multiple animal cell large-scale culture - Google Patents
Non-serum culture medium for multiple animal cell large-scale culture Download PDFInfo
- Publication number
- CN1778902A CN1778902A CNA2005100301989A CN200510030198A CN1778902A CN 1778902 A CN1778902 A CN 1778902A CN A2005100301989 A CNA2005100301989 A CN A2005100301989A CN 200510030198 A CN200510030198 A CN 200510030198A CN 1778902 A CN1778902 A CN 1778902A
- Authority
- CN
- China
- Prior art keywords
- acid
- sigma
- sodium
- hcl
- serum free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域technical field
本发明涉及动物细胞大规模高密度培养过程中用于生产抗体、疫苗、基因重组蛋白等生物产品的无血清培养基。The invention relates to a serum-free medium used for producing biological products such as antibodies, vaccines, and gene recombinant proteins during large-scale high-density culture of animal cells.
技术背景technical background
动物细胞培养已经被广泛应用于生产各类生物活性物质如单克隆抗体、病毒疫苗、病毒载体、免疫调节因子、生长因子、特定肿瘤抗原以及各种基因重组蛋白质药物等,传统培养过程中通常需要添加一定量(5%-10%)的牛血清,血清中含有细胞生长所需的生长因子、激素、载体蛋白、贴壁因子、微量元素以及其它的营养物质,可以极大地促进细胞的生长和产物的表达。Animal cell culture has been widely used in the production of various biologically active substances such as monoclonal antibodies, virus vaccines, virus vectors, immune regulators, growth factors, specific tumor antigens, and various gene recombinant protein drugs. Add a certain amount (5%-10%) of bovine serum, which contains growth factors, hormones, carrier proteins, adhesion factors, trace elements and other nutrients required for cell growth, which can greatly promote cell growth and product expression.
然而,血清的应用也带来很多缺点:However, the application of serum also brings many disadvantages:
(1)血清易受病毒、支原体或其它病原体的污染;(1) Serum is susceptible to contamination by viruses, mycoplasma or other pathogens;
(2)不同批号血清间差异造成产品批次间的差异;(2) Differences between different batches of serum cause differences between product batches;
(3)大量血清蛋白的存在增加了下游分离纯化的难度,使其成本升高,回收率降低;(3) The existence of a large amount of serum protein increases the difficulty of downstream separation and purification, which increases the cost and reduces the recovery rate;
(4)部分血清蛋白难以通过分离纯化手段彻底去除,严重影响产品的最终质量。(4) Some serum proteins are difficult to completely remove by means of separation and purification, which seriously affects the final quality of the product.
为了克服血清所带来的各种缺点,八十年代起就有许多研究者从事无血清培养基的研究开发工作,Darfler等开发了CITTL无血清培养基,它以DMEM/F12(1∶1)为基础培养基,添加1.5mg/L的胰岛素,3.0mg/L的转铁蛋白,2nmol/L的睾酮,5mg/L的过氧化氢酶,1.5mg/L的β-甘油磷酸,0.5mg/L的二亚油酰磷脂胆碱,用于杂交瘤细胞的培养;Murakami等开发了DMEM/F12-ITES无血清培养基,它是在DMEM/F12的基础上添加了5mg/L的胰岛素,2-35mg/L的转铁蛋白,20μmol/L乙醇胺,1nmol/L亚硒酸钠,该培养基被广泛应用于培养杂交瘤细胞。In order to overcome the various shortcomings brought about by serum, many researchers have been engaged in the research and development of serum-free medium since the eighties. As the basal medium, add 1.5mg/L insulin, 3.0mg/L transferrin, 2nmol/L testosterone, 5mg/L catalase, 1.5mg/L β-glycerophosphate, 0.5mg/L The dilinoleoylphosphatidylcholine of L is used for the cultivation of hybridoma cells; Murakami et al. developed DMEM/F12-ITES serum-free medium, which added 5mg/L insulin on the basis of DMEM/F12, 2 -35mg/L transferrin, 20μmol/L ethanolamine, 1nmol/L sodium selenite, this medium is widely used in culturing hybridoma cells.
另外,美国专利U.S.P.5,063,157所涉及的无血清培养基用于哺乳动物细胞悬浮培养,在基础培养基中添加了转铁蛋白、胰岛素、蛋白胨、beta-D-xylopyranose derivative、硒和多胺,是一款低蛋白培养基;美国专利U.S.P.4,443,546则是另一款类似的低蛋白培养基;美国专利U.S.P.4,657,866涉及一种全部组分明确(chemical defined medium)的合成培养基用于培养动物和人的一些细胞系;欧洲专利E.P.481,791公开一种用于CHO细胞的无血清培养基,它含有水、渗透压调节剂、缓冲剂、糖、氨基酸、铁、生长因子和其它必需成分。In addition, the serum-free medium involved in U.S. Patent U.S.P.5,063,157 is used for suspension culture of mammalian cells, and transferrin, insulin, peptone, beta-D-xylopyranose derivative, selenium and polyamines are added to the basal medium, which is a U.S. Patent U.S.P.4,443,546 is another similar low protein medium; U.S. Patent U.S.P.4,657,866 relates to a synthetic medium with clear (chemical defined medium) for cultivating some of animals and humans Cell lines; European Patent E.P.481,791 discloses a serum-free medium for CHO cells containing water, osmotic regulators, buffers, sugars, amino acids, iron, growth factors and other essential components.
目前,已有大量的商业化无血清培养基被开发并应用于各类动物细胞培养,如GIBCO公司用于杂交瘤细胞的CD Hybridoma培养基、Hybridoma-SFM培养基、PFHM-IIProtein-free培养基,用于CHO细胞的CD CHO培养基、CHO-s-SFMII培养基;SIGMA公司的Hybri-Max等等。At present, a large number of commercial serum-free media have been developed and applied to various animal cell cultures, such as CD Hybridoma medium, Hybridoma-SFM medium, and PFHM-IIProtein-free medium for hybridoma cells from GIBCO. , CD CHO medium, CHO-s-SFMII medium for CHO cells; Hybri-Max from SIGMA, etc.
上述无血清培养基都有各自的优点,大都能很好地支持细胞的生长,但同时它们也存在很多缺点:The above serum-free media have their own advantages, and most of them can support the growth of cells well, but they also have many disadvantages:
(1)因价格昂贵,只适合实验室小规模使用;而不适合大规模生物反应器;(1) Due to the high price, it is only suitable for small-scale use in laboratories; it is not suitable for large-scale bioreactors;
(2)培养基没有针对细胞进行优化,所支持的细胞密度较低,导致生产过程产率不高;(2) The medium is not optimized for cells, and the supported cell density is low, resulting in low yield in the production process;
(3)有些培养基虽然能很好地支持细胞生长,但往往会导致细胞表达产物的能力降低,甚至丧失;(3) Although some media can support cell growth well, it often leads to the reduction or even loss of the ability of cells to express products;
(4)培养基对细胞有很高的特异性,通常一种培养基只适合一个细胞株或细胞系,而不适合其它的细胞株或细胞系。(4) The medium is highly specific to cells, and usually a medium is only suitable for one cell strain or cell line, but not for other cell strains or cell lines.
发明内容Contents of the invention
本发明需要解决的技术问题在于公开一种适用于多种动物细胞大规模培养的无血清培养基,以克服现有技术存在的上述缺陷。The technical problem to be solved in the present invention is to disclose a serum-free medium suitable for large-scale cultivation of various animal cells, so as to overcome the above-mentioned defects in the prior art.
本发明的适用于多种动物细胞大规模培养的无血清培养基是以重量比为=1∶1的DMEM和F12的为基础培养基,添加胰岛素、转铁蛋白、乙醇胺、丙酮酸钠白蛋白、β-巯基乙醇、微量元素、激素、必需氨基酸等成分;The serum-free medium suitable for large-scale cultivation of various animal cells of the present invention is based on DMEM and F12 with a weight ratio of 1:1, and insulin, transferrin, ethanolamine, sodium pyruvate and albumin are added , β-mercaptoethanol, trace elements, hormones, essential amino acids and other ingredients;
培养基DMEM和F12的组分在GIBCO或SIGMA公司产品目录上均已公开,有关人员可参阅,本发明不再赘述,可采用商业化的产品,如GIBCO或SIGMA公司的产品;The components of the culture medium DMEM and F12 have been disclosed in the product catalog of GIBCO or SIGMA, and relevant personnel can refer to them. The present invention will not repeat them, and commercial products can be used, such as products of GIBCO or SIGMA;
本发明最终形成的无血清培养基的组分和含量如下:
本发明的培养基的制备方法是十分简单的,可采用常规的方法将上述组分溶解无热源超纯水即可制备而成。The preparation method of the culture medium of the present invention is very simple, and can be prepared by dissolving the above-mentioned components in non-pyrogenic ultrapure water by conventional methods.
本发明的培养基可用于杂交瘤细胞、rCHO细胞、293细胞等细胞系或细胞株的传代培养和高密度连续灌注培养。它具有以下优点:The culture medium of the invention can be used for subculture and high-density continuous perfusion culture of hybridoma cells, rCHO cells, 293 cells and other cell lines or cell strains. It has the following advantages:
1.能支持多个细胞株或细胞系的生长;1. Can support the growth of multiple cell lines or cell lines;
2.在细胞生长、产物表达方面与含血清培养基接近或相当;2. It is close to or equivalent to serum-containing medium in terms of cell growth and product expression;
3.支持细胞的长期传代培养;3. Support the long-term subculture of cells;
4.含有较低浓度的蛋白质,有利于产物的分离纯化,提高产品的品质;4. Contains a lower concentration of protein, which is conducive to the separation and purification of the product and improves the quality of the product;
5.价格低廉,适合于大规模工业化生产;5. Low price, suitable for large-scale industrial production;
最重要的是,本发明所形成的无血清培养基适用于多个细胞株或细胞系的连续灌注培养,可获得较高的细胞密度和产物浓度,能显著提高生产过程效率和产品产率。Most importantly, the serum-free medium formed by the present invention is suitable for continuous perfusion culture of multiple cell lines or cell lines, can obtain higher cell density and product concentration, and can significantly improve production process efficiency and product yield.
附图说明Description of drawings
图1为HB58杂交瘤细胞连续灌注培养的细胞生长与产物表达曲线。Figure 1 is the cell growth and product expression curves of continuous perfusion culture of HB58 hybridoma cells.
图2为CHO细胞连续灌注培养的细胞生长与产物表达曲线。Figure 2 is the cell growth and product expression curves of continuous perfusion culture of CHO cells.
图3为批培养中293细胞的生长曲线。Figure 3 is the growth curve of 293 cells in batch culture.
具体实施方式Detailed ways
实施例1Example 1
本发明所述的无血清培养基可用于杂交瘤细胞的高密度连续灌注培养,培养基的组成成分如下:
将上述组分混合并溶解无热源超纯水,即可获得培养基。The above components are mixed and dissolved in pyrogen-free ultrapure water to obtain a culture medium.
将HB58杂交瘤细胞(从ATCC获得)在本发明所述的无血清培养基中传代适应后,在BF-2(德国B.BRAUN公司)2升生物反应器中接种,接种密度2.0×105cells/ml,培养56小时后开始灌注,灌注速率为0.5(1/day),灌注培养基即为本发明所述的无血清培养基,培养至200小时后细胞密度维持在1.2×107cells/ml左右,单克隆抗体浓度维持在500mg/L左右(见图1),与普通培养基批培养的结果相比,细胞密度和单抗浓度均提高8倍以上。图中,曲线1为活细胞密度,曲线2为总细胞密度,曲线3为单抗表达量。HB58 hybridoma cells (obtained from ATCC) were subcultured and adapted in the serum-free medium according to the present invention, and then inoculated in a 2-liter bioreactor of BF-2 (Germany B.BRAUN Company) with an inoculation density of 2.0×10 5 cells/ml, perfusion starts after 56 hours of culture, the perfusion rate is 0.5 (1/day), the perfusion medium is the serum-free medium of the present invention, and the cell density is maintained at 1.2×10 7 cells after 200 hours of culture /ml, the monoclonal antibody concentration was maintained at about 500mg/L (see Figure 1), compared with the results of batch culture in ordinary medium, the cell density and monoclonal antibody concentration were increased by more than 8 times. In the figure, curve 1 is the living cell density,
实施例2Example 2
本发明所述的无血清培养基可用于rCHO细胞的高密度连续灌注培养,培养基的组成成分如下:
将rCHO细胞(rCHO SS3 A2,表达人抗凝血因子III)在本发明所述的无血清培养基中传代适应后,在B.BRAUN 2升生物反应器中接种,接种密度2.0×105cells/ml,培养40小时后开始灌注,灌注速率为0.58(1/day),灌注培养基即为本发明所述的无血清培养基,培养至255小时后细胞密度维持在0.9-1.0×107cells/ml左右,产物浓度维持在350-380U/L左右(见图2),与普通培养基批培养的结果相比,细胞密度和单抗浓度分别提高6倍和5倍。图中,曲线4为活细胞密度,曲线总细胞密度,曲线6为产物表达量。rCHO cells (rCHO SS3 A2, expressing human anticoagulant factor III) were subcultured in the serum-free medium described in the present invention, and then seeded in a B.BRAUN 2-liter bioreactor at a seeding density of 2.0×10 5 cells /ml, start perfusion after 40 hours of culture, the perfusion rate is 0.58 (1/day), the perfusion medium is the serum-free medium of the present invention, and the cell density is maintained at 0.9-1.0×10 7 after 255 hours of culture The cells/ml is about 350-380U/L, and the product concentration is maintained at about 350-380U/L (see Figure 2). Compared with the results of ordinary medium batch culture, the cell density and monoclonal antibody concentration are increased by 6 times and 5 times respectively. In the figure,
实施例3Example 3
本发明所述的无血清培养基可用于293细胞的培养,培养基的组成成分如下:
将293细胞在本发明所述的无血清培养基中传代适应后,在B.BRAUN 2升生物反应器中接种进行批培养,接种密度为2.45×105cells/ml,由图3可以看出细胞的生长几乎看不到迟滞期,接种后即进入指数生长期,平均比生长速率为0.46day-1,最大活细胞密度为11.0×105cells/ml。图中,曲线7为活细胞密度,曲线8为活细胞比例。After the 293 cells were subcultured and adapted in the serum-free medium of the present invention, they were inoculated in a B.BRAUN 2-liter bioreactor for batch culture, and the inoculation density was 2.45×10 5 cells/ml, as can be seen from Figure 3 There was almost no lag phase in the growth of the cells. After inoculation, the cells entered the exponential growth phase, with an average specific growth rate of 0.46day -1 and a maximum viable cell density of 11.0×10 5 cells/ml. In the figure, curve 7 is the living cell density, and
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100301989A CN100362098C (en) | 2005-09-29 | 2005-09-29 | Serum-free medium suitable for large-scale culture of various animal cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100301989A CN100362098C (en) | 2005-09-29 | 2005-09-29 | Serum-free medium suitable for large-scale culture of various animal cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1778902A true CN1778902A (en) | 2006-05-31 |
| CN100362098C CN100362098C (en) | 2008-01-16 |
Family
ID=36769357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100301989A Expired - Fee Related CN100362098C (en) | 2005-09-29 | 2005-09-29 | Serum-free medium suitable for large-scale culture of various animal cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100362098C (en) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101386836B (en) * | 2007-09-12 | 2010-11-24 | 北京清大天一科技有限公司 | Zooblast culture medium dry powder composition, culture medium composition and preparation method thereof |
| CN101113432B (en) * | 2007-06-25 | 2011-04-27 | 南华大学 | A serum-free or low serum concentration cell culture method |
| CN101386837B (en) * | 2007-09-12 | 2011-06-29 | 北京清大天一科技有限公司 | Zooblast cultivation method |
| CN102115728B (en) * | 2009-12-31 | 2012-09-26 | 北京清大天一科技有限公司 | Serum-free animal cell culture medium dry powder, liquid culture medium and preparation method thereof |
| CN103468638A (en) * | 2013-09-23 | 2013-12-25 | 天津瑞普生物技术股份有限公司 | Large-scale suspension cultivation method of 293 cells |
| CN104513805A (en) * | 2013-10-07 | 2015-04-15 | 鲁南制药集团股份有限公司 | Method for producing anti CD20 antibody |
| CN105246510A (en) * | 2013-03-15 | 2016-01-13 | 豪夫迈·罗氏有限公司 | Cell Culture Media and Antibody Production Methods |
| CN105462916A (en) * | 2015-12-22 | 2016-04-06 | 肇庆大华农生物药品有限公司 | Serum-free medium for culturing Marc-145 cell and preparation method thereof |
| CN106635958A (en) * | 2016-12-24 | 2017-05-10 | 严志海 | CHO (Chinese Hamster Ovary) cell culture medium |
| CN107099508A (en) * | 2017-06-23 | 2017-08-29 | 曲宝赤 | A kind of Serum-free Hybridoma cell culture medium |
| CN107308447A (en) * | 2017-07-10 | 2017-11-03 | 广州博恒生物科技有限公司 | A kind of preparation method of triple inactivated vaccine |
| CN108384747A (en) * | 2018-03-05 | 2018-08-10 | 安徽省农业科学院园艺研究所 | Express the Chinese hamster ovary celI serum free suspension cultural method of Rabies virus antibody |
| CN108699529A (en) * | 2016-02-17 | 2018-10-23 | 普乐思尔活性生物科学有限公司 | The culture medium that chemical composition for cultivating the cell mass for containing cancer stem cell (CSC) determines |
| CN109234223A (en) * | 2018-11-21 | 2019-01-18 | 南京基蛋生物医药有限公司 | Low albumen serum-free cell culture medium |
| CN110117573A (en) * | 2019-04-15 | 2019-08-13 | 河北省科学院生物研究所 | A kind of serum-free cell culture medium and its application |
| CN110894484A (en) * | 2019-11-25 | 2020-03-20 | 杭州职业技术学院 | Universal plant culture medium and tissue culture |
| CN111826341A (en) * | 2020-07-23 | 2020-10-27 | 上海奥浦迈生物科技有限公司 | Method for in vitro culture of HEK293 cells for transient expression of proteins |
| CN114480294A (en) * | 2021-12-15 | 2022-05-13 | 上海捷门生物技术有限公司 | Serum-free culture medium suitable for adherent growth of hybridoma cells |
| CN114540274A (en) * | 2022-02-17 | 2022-05-27 | 上海健士拜生物科技有限公司 | Serum-free medium, preparation method thereof and method for culturing 2BS (2 BS) cells by using serum-free medium |
| WO2022134229A1 (en) * | 2020-12-23 | 2022-06-30 | 武汉睿健医药科技有限公司 | Neural stem cell-induced differential medium and induction differentiation method |
| CN116790483A (en) * | 2023-08-22 | 2023-09-22 | 苏州依科赛生物科技股份有限公司 | CHO cell serum-free medium and application thereof |
| US12545892B2 (en) | 2020-05-19 | 2026-02-10 | Iregene Therapeutics Ltd | Application of TGF-B inhibitor in inducing neural stem cells and organoid formation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61124378A (en) * | 1984-11-22 | 1986-06-12 | Agency Of Ind Science & Technol | Culture medium composition for cell originated from blood stem cell |
| JP2599123B2 (en) * | 1985-12-28 | 1997-04-09 | 萩原 義秀 | Novel human B cell / lymphoblast cell mutant |
| WO1996040866A1 (en) * | 1995-06-07 | 1996-12-19 | Novartis Ag | Serum-free media for primitive hematopoietic cells and methods of use thereof |
| US6153582A (en) * | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
| CN1431299A (en) * | 2003-01-17 | 2003-07-23 | 江西医学院 | Serum-free medium of human epidermis cell and its cultivating method and application |
| CN1563365A (en) * | 2004-03-12 | 2005-01-12 | 西北农林科技大学 | A method for separating and purifying skin epidermal stem cells |
-
2005
- 2005-09-29 CN CNB2005100301989A patent/CN100362098C/en not_active Expired - Fee Related
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101113432B (en) * | 2007-06-25 | 2011-04-27 | 南华大学 | A serum-free or low serum concentration cell culture method |
| CN101386836B (en) * | 2007-09-12 | 2010-11-24 | 北京清大天一科技有限公司 | Zooblast culture medium dry powder composition, culture medium composition and preparation method thereof |
| CN101386837B (en) * | 2007-09-12 | 2011-06-29 | 北京清大天一科技有限公司 | Zooblast cultivation method |
| CN102115728B (en) * | 2009-12-31 | 2012-09-26 | 北京清大天一科技有限公司 | Serum-free animal cell culture medium dry powder, liquid culture medium and preparation method thereof |
| CN105246510A (en) * | 2013-03-15 | 2016-01-13 | 豪夫迈·罗氏有限公司 | Cell Culture Media and Antibody Production Methods |
| CN103468638A (en) * | 2013-09-23 | 2013-12-25 | 天津瑞普生物技术股份有限公司 | Large-scale suspension cultivation method of 293 cells |
| CN103468638B (en) * | 2013-09-23 | 2016-01-20 | 天津瑞普生物技术股份有限公司 | A kind of extensive suspension culture method of 293 cells |
| CN104513805A (en) * | 2013-10-07 | 2015-04-15 | 鲁南制药集团股份有限公司 | Method for producing anti CD20 antibody |
| CN105462916A (en) * | 2015-12-22 | 2016-04-06 | 肇庆大华农生物药品有限公司 | Serum-free medium for culturing Marc-145 cell and preparation method thereof |
| CN105462916B (en) * | 2015-12-22 | 2018-04-13 | 肇庆大华农生物药品有限公司 | A kind of serum free medium of culture 145 cells of Marc and preparation method thereof |
| CN108699529A (en) * | 2016-02-17 | 2018-10-23 | 普乐思尔活性生物科学有限公司 | The culture medium that chemical composition for cultivating the cell mass for containing cancer stem cell (CSC) determines |
| CN108699529B (en) * | 2016-02-17 | 2022-05-24 | 普乐思尔有限公司 | Chemically-defined media for culturing cell populations comprising Cancer Stem Cells (CSCs) |
| CN106635958A (en) * | 2016-12-24 | 2017-05-10 | 严志海 | CHO (Chinese Hamster Ovary) cell culture medium |
| CN107099508A (en) * | 2017-06-23 | 2017-08-29 | 曲宝赤 | A kind of Serum-free Hybridoma cell culture medium |
| CN107308447A (en) * | 2017-07-10 | 2017-11-03 | 广州博恒生物科技有限公司 | A kind of preparation method of triple inactivated vaccine |
| CN108384747A (en) * | 2018-03-05 | 2018-08-10 | 安徽省农业科学院园艺研究所 | Express the Chinese hamster ovary celI serum free suspension cultural method of Rabies virus antibody |
| CN109234223A (en) * | 2018-11-21 | 2019-01-18 | 南京基蛋生物医药有限公司 | Low albumen serum-free cell culture medium |
| CN109234223B (en) * | 2018-11-21 | 2021-01-19 | 南京基蛋生物医药有限公司 | Low-protein serum-free cell culture medium |
| WO2020103439A1 (en) * | 2018-11-21 | 2020-05-28 | 苏恩本 | Low-protein serum-free cell culture medium |
| CN110117573A (en) * | 2019-04-15 | 2019-08-13 | 河北省科学院生物研究所 | A kind of serum-free cell culture medium and its application |
| CN110894484A (en) * | 2019-11-25 | 2020-03-20 | 杭州职业技术学院 | Universal plant culture medium and tissue culture |
| US12545892B2 (en) | 2020-05-19 | 2026-02-10 | Iregene Therapeutics Ltd | Application of TGF-B inhibitor in inducing neural stem cells and organoid formation |
| CN111826341A (en) * | 2020-07-23 | 2020-10-27 | 上海奥浦迈生物科技有限公司 | Method for in vitro culture of HEK293 cells for transient expression of proteins |
| CN114736864B (en) * | 2020-12-23 | 2024-01-26 | 武汉睿健医药科技有限公司 | Neural stem cell induction differentiation medium and induction differentiation method |
| WO2022134229A1 (en) * | 2020-12-23 | 2022-06-30 | 武汉睿健医药科技有限公司 | Neural stem cell-induced differential medium and induction differentiation method |
| CN114736864A (en) * | 2020-12-23 | 2022-07-12 | 武汉睿健医药科技有限公司 | Neural stem cell induced differentiation culture medium and induced differentiation method |
| US12590954B2 (en) | 2020-12-23 | 2026-03-31 | Iregene Therapeutics, Co., Ltd. | Neural stem cell-induced differential medium and induction differentiation method |
| CN114480294A (en) * | 2021-12-15 | 2022-05-13 | 上海捷门生物技术有限公司 | Serum-free culture medium suitable for adherent growth of hybridoma cells |
| CN114480294B (en) * | 2021-12-15 | 2024-01-26 | 上海捷门生物技术有限公司 | Serum-free culture medium suitable for hybridoma cell wall-attached growth |
| CN114540274A (en) * | 2022-02-17 | 2022-05-27 | 上海健士拜生物科技有限公司 | Serum-free medium, preparation method thereof and method for culturing 2BS (2 BS) cells by using serum-free medium |
| CN114540274B (en) * | 2022-02-17 | 2023-10-20 | 上海健士拜生物科技有限公司 | Serum-free medium, preparation method thereof and method for culturing 2BS cells by using serum-free medium |
| CN116790483B (en) * | 2023-08-22 | 2023-10-20 | 苏州依科赛生物科技股份有限公司 | CHO cell serum-free medium and application thereof |
| CN116790483A (en) * | 2023-08-22 | 2023-09-22 | 苏州依科赛生物科技股份有限公司 | CHO cell serum-free medium and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100362098C (en) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100362098C (en) | Serum-free medium suitable for large-scale culture of various animal cells | |
| CN101603026B (en) | Animal origin-free low-protein culture medium suitable for animal cell product production | |
| US7598083B2 (en) | Chemically defined media compositions | |
| CN101418330B (en) | Non protein culture medium adapted to large-scale culture of NSO cell and production of antibody | |
| CN109337861B (en) | CHO cell serum-free medium supporting high expression of product | |
| CN102827804B (en) | Culture medium and method suitable for the amplification culture of Vero cell microcarrier suspension | |
| US20150329830A1 (en) | Myeloma cell culture in transferrin-free low iron medium | |
| JPH06511389A (en) | animal cell culture | |
| CN106957815B (en) | Formula of serum-free culture medium for human pluripotent stem cells | |
| JP2012503487A (en) | High titer antibody production | |
| CN101974481A (en) | Serum free culture medium for growing various cells derived from kidney tissue | |
| CN109234223B (en) | Low-protein serum-free cell culture medium | |
| CN112795531A (en) | CHO cell serum-free and protein-free culture medium and application thereof | |
| CN104328158B (en) | Specific chemical components culture medium suitable for the large-scale production of animal cell expression product | |
| CN102021139A (en) | Chinese hamster ovary culture medium as well as preparation method and application thereof | |
| CN1962857A (en) | Serum-free medium for mammalian cell | |
| EP0659880B1 (en) | Medium for culturing animal cells or antibody-producing cells | |
| CN1087778C (en) | Hybridizing tumour cell non-serum culture medium | |
| CN109370985A (en) | Serum-free medium for large-scale culture of human umbilical cord mesenchymal stem cells | |
| CN106399224A (en) | Serum-free and protein-free cell culture medium | |
| CN113913368A (en) | Serum-free medium suitable for CHO cell large-scale suspension amplification culture and preparation and application thereof | |
| EP0550638A4 (en) | Medium for culture of mammalian cells | |
| CN102653729B (en) | Culture medium used for Chinese hamster ovary cells | |
| CN111492050A (en) | A streamlined method for preparing liquid media | |
| CN1362514A (en) | Serumless medium suitable for growth and maintenance of young hamster kidney cell |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |